peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Diet Dietary restriction and supplementation are key measures taken in several well-known metabolic disorders, including galactosemia, phenylketonuria (PKU), maple syrup urine disease, organic acidurias and urea cycle disorders. Such restrictive diets can be difficult for the patient and family to maintain, and require close consultation with a nutritionist who has special experience in metabolic disorders. The composition of the diet will change depending on the caloric needs of the growing child and special attention is needed during a pregnancy if a woman is affected with one of these disorders.
=== Thermogravimetric analysis === Thermogravimetric analysis (TGA) is one of the most common techniques to investigate pyrolysis with no limitations of heat and mass transfer. The results can be used to determine mass loss kinetics. Activation energies can be calculated using the Kissinger method or peak analysis-least square method (PA-LSM). TGA can couple with Fourier-transform infrared spectroscopy (FTIR) and mass spectrometry. As the temperature increases, the volatiles generated from pyrolysis can be measured.
The vacuum flask consists of two vessels, one placed within the other and joined at the neck. The gap between the two vessels is partially evacuated of air, creating a partial-vacuum which reduces heat conduction or convection. Heat transfer by thermal radiation may be minimized by silvering flask surfaces facing the gap but can become problematic if the flask's contents or surroundings are very hot; hence vacuum flasks usually hold contents below the boiling point of water. Most heat transfer occurs through the neck and opening of the flask, where there is no vacuum. Vacuum flasks are usually made of metal, borosilicate glass, foam or plastic and have their opening stoppered with cork or polyethylene plastic. Vacuum flasks are often used as insulated shipping containers. Extremely large or long vacuum flasks sometimes cannot fully support the inner flask from the neck alone, so additional support is provided by spacers between the interior and exterior shell. These spacers act as a thermal bridge and partially reduce the insulating properties of the flask around the area where the spacer contacts the interior surface. Several technological applications, such as NMR and MRI machines, rely on the use of double vacuum flasks. These flasks have two vacuum sections. The inner flask contains liquid helium and the outer flask contains liquid nitrogen, with one vacuum section in between. The loss of precious helium is limited in this way.
They were supported by the 123rd Special Tactics Squadron, 173rd Airborne Brigade and several companies of 2nd Battalion, 14th Infantry Regiment, 10th Mountain Division. The original plan called for TF Viking to support the 4th Infantry Division advance from Turkey towards Baghdad but the mission was cancelled when Turkey denied staging rights to the US. Viking was assigned the task of keeping 13 Iraqi armoured and infantry divisions in the north from reinforcing Baghdad, the 10th SFG was to organise the Kurdish Peshmerga to support them. Just as in Afghanistan, SF were the first military units in Iraq after the initial entry of JSOC (Joint Special Operations Command) and the CIA. At H-Hour, Bravo and Charlie companies of 1st Battalion, 5th SFG, crossed the Kuwait border began carrying out operations in western Iraq – joining up with the British and Australian SAS and Delta Force elements to secure H-3 Air Base, as well as securing Ar Rutbah; the 5th SFG also carried out operations in support of forces moving on Karbala Nasiriyah and Al Diwaniyah. On 21 March, ODA 554 of Charlie Company, 2nd Battalion 5th SFG entered Iraq and began carrying out operations in southern Iraq – mainly supporting British forces in the seizure of Basra and surrounding locations, until relieved by G squadron, 22 SAS Regiment.
In 1887, a laboratory for the study of bacteria, the Hygienic Laboratory, was established within the Marine Hospital Service, which at the time was expanding its functions beyond the system of Marine Hospitals into quarantine and research programs. It was initially located at the New York Marine Hospital on Staten Island. In 1891, it moved to the top floor of the Butler Building in Washington, D.C. In 1904, it moved again to a new campus at the Old Naval Observatory, which grew to include five major buildings. In 1901, the Division of Scientific Research was formed, which included the Hygienic Laboratory as well as other research offices of the Marine Hospital Service. In 1912, the Marine Hospital Service became the Public Health Service (PHS). In 1922, PHS established a Special Cancer Investigations laboratory at Harvard Medical School. This development marked the beginning of partnerships with universities. In 1930, the Hygienic Laboratory was re-designated as the National Institute of Health by the Ransdell Act, and was given $750,000 to construct two NIH buildings at the Old Naval Observatory campus. In 1937, the NIH absorbed the rest of the Division of Scientific Research, of which it was formerly part. In 1938, the NIH moved to its current campus in Bethesda, Maryland. Over the next few decades, Congress would markedly increase funding of the NIH. Various institutes and centers within the NIH were created for specific research programs. In 1944, the Public Health Service Act was approved and the National Cancer Institute became a division of the NIH.
Sources: en.wikipedia.org
Like its drug subcategory prototype methadone, phenadoxone can be used as the opioid analgesic in Brompton cocktail. Phenadoxone is most used at the current time in Denmark and various countries in eastern Europe.
== Adverse effects == Depolarizing drug Succinylcholine: Succinylcholine presents several undesirable side effects which affect its application as it interacts with both muscarinic and nicotinic receptors, due to its acetylcholine-mimicking properties. Firstly, hyperkalemia is the most seen adverse effect of succinylcholine due to its stimulatory effect of the drug on skeletal muscles. This results in an increase in serum potassium levels as high as 0.5 mEq/L. This increase is clinically insignificant in normal patients but can be detrimental for patients with predisposed hyperkalemia caused by up-regulation of post-junctional acetylcholine receptors. Therefore, succinylcholine use is contraindicated for this category of patients. Further consideration is also required for patients with chronically elevated potassium or traumatic injuries, as there is a high probability of acute hyperkalemia which can lead to dysrhythmia or death. Secondly, succinylcholine causes the activation of muscarinic receptors in the SA node, causing bradycardia. This effect is especially highlighted in use with patients with high vagal tone (traumatic or young patients). In adults with a normal vagal tone, bradycardia has only been reported on repeated incremental dosages of succinylcholine. Anticholinergic drugs such as atropine and glycopyrrolate can be used as secondary therapy in treating or prophylaxis of bradycardia.
An intentional controlled detonation of illegal fireworks by the Los Angeles Police Department in a busy neighborhood of South Los Angeles does not go as planned, injuring seventeen people, including 10 LAPD officers, and damaging windows, cars, and buildings.
=== Detectors === HPLC detectors fall into two main categories: universal or selective. Universal detectors typically measure a bulk property (e.g., refractive index) by measuring a difference of a physical property between the mobile phase and mobile phase with solute while selective detectors measure a solute property (e.g., UV-Vis absorbance) by simply responding to the physical or chemical property of the solute. HPLC most commonly uses a UV-Vis absorbance detector; however, a wide range of other chromatography detectors can be used. A universal detector that complements UV-Vis absorbance detection is the charged aerosol detector (CAD). A kind of commonly utilized detector includes refractive index detectors, which provide readings by measuring the changes in the refractive index of the eluant as it moves through the flow cell. In certain cases, it is possible to use multiple detectors, for example LCMS normally combines UV-Vis with a mass spectrometer. When used with an electrochemical detector (ECD) the HPLC-ECD selectively detects neurotransmitters such as: norepinephrine, dopamine, serotonin, glutamate, GABA, acetylcholine and others in neurochemical analysis research applications. The HPLC-ECD detects neurotransmitters to the femtomolar range. Other methods to detect neurotransmitters include liquid chromatography-mass spectrometry, ELISA, or radioimmunoassays.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.